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ABSTRACT: Reduced SIRT1 activity and levels during osteoarthritis (OA) promote gradual loss of cartilage. Loss of
cartilage matrix is accompanied by an increase in matrix metalloproteinase (MMP) 13, partially because of enhanced
LEF1 transcriptional activity. In this study,we assessed the role of SIRT1 in LEF1-mediatedMMP13gene expression in
human OA chondrocytes. Results showed that MMP13 protein levels and enzymatic activity decreased significantly
during SIRT1 overexpression or activation by resveratrol. Conversely, MMP13 gene expression was reduced in
chondrocytes transfected with SIRT1 siRNA or treated with nicotinamide (NAM), a sirtuin inhibitor. Chondrocytes
challenged with IL-1b, a cytokine involved in OA pathogenesis, enhanced LEF1 protein levels and gene expression,
resulting in increased MMP13 gene expression; however, overexpression of SIRT1 during IL-1b challenge impeded
LEF1 levels and MMP13 gene expression. Previous reports showed that LEF1 binds to the MMP13 promoter and
transactivates its expression, but we observed that SIRT1 repressed LEF1 protein and mRNA expression, ultimately
reducing LEF1 transcriptional activity, as judged by luciferase assay. Finally, mouse articular cartilage from Sirt12/2
presented increased LEF1 andMMP13 protein levels, similar to humanOA cartilage. Thus, demonstrating for the first
time that SIRT1 repressesMMP13 in humanOA chondrocytes, which appears to bemediated, at least in part, through
repression of the transcription factor LEF1, a known modulator of MMP13 gene expression.—Elayyan, J., Lee, E.-J.,
Gabay,O., Smith,C.A.,Qiq,O.,Reich, E.,Mobasheri,A.,Henrotin,Y.,Kimber, S. J.,Dvir-Ginzberg,M.LEF1-mediated
MMP13geneexpression is repressedbySIRT1 inhumanchondrocytes. FASEB J. 31, 3116–3125 (2017).www.fasebj.org
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Articular cartilage undergoes age-related degenerative
changes leading to the joint disease osteoarthritis (OA).
Gradual loss of hyaline joint cartilage during OA is
evoked through chronic synovitis, which involves the ac-
cumulation of proinflammatory cytokines, as IL1b, TNF-a,
and IL6 within the joint (1–5), subsequently leading to
a steady increase in matrix metalloproteinases (MMPs)
and a disintegrin and MMP with thrombospondin mo-
tifs (ADAMTS) proteins, which further promote
cartilage destruction (6–12). Recent experimental attempts
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succeeded in halting cartilage destruction in mouse OA
models using intra-articular injections of a natural Sirt1 ac-
tivator, resveratrol (Res) (13). Correspondingly, additional
in vivo studies (14) demonstrated that Sirt1 exerts an
anti-inflammatory effect in cartilage duringOA.Moreover,
mechanistic studies have provided further support that
SIRT1 promotes chondrocyte survival through various
pathways (15–19)—in particular, deacetylation of p65/
RelA—which reduces iNOS gene expression after IL-1b
challenge of chondrocytes (20). Despite the wealth of in-
formation regarding the beneficial effects exerted by SIRT1
in maintaining chondrocyte survival and attenuating in-
flammation, very little is known about the impact of SIRT1
on cartilage destruction during OA.
Nevertheless, several reports have shown that theWnt/
b-catenin signaling pathway is involved in IL-1b-mediated
cartilage degeneration (21–26). These studies initially
identified a 39 regulatorypromoter site ofMMP13, towhich
lymphoid enhancer factor (LEF)-1 binds, thus inducing
MMP13 gene expression (25). Moreover, Yun et al. (26)
showed that IL-1b augments LEF1 levels and induces nu-
clear translocation of NF-kB in chondrocytes. Consequen-
tial studies by this group revealed that IL-1b inducesNF-kB
and activator protein 1 (AP-1) levels in chondrocytes and
that both proteins interact with LEF1 to facilitate MMP13
gene expressionvia aDNA loopingmechanism, rather than
gene activation mediated by the canonical Wnt pathway.
Reduced SIRT1 activity has been found to correlate with
increased expression of various cartilage-degrading en-
zymes, such as MMP13 and ADAMTS4 (27), but little is
known of the mechanism by which this is achieved; more-
over, there is no indication to date that LEF1 may be an
intermediate factor facilitating this effect. These correlative
observations (27), led us to hypothesize that SIRT1 may be
an indirect negative regulator of MMP13 via its conceivable
capacity to repress LEF1. Indeed, this report shows that
SIRT1 reduced MMP13 gene expression and LEF1 protein
levels in human primary chondrocytes. Furthermore, in-
flammation of the joint may lead to SIRT1 truncation (27),
possibly reducing SIRT1 chromatin binding (28), sequen-
tially lifting its inhibitory effects on LEF1 gene expression
and promoting downstreamMMP13 gene expression.
MATERIALS AND METHODS
Reagents, cell culture, and transfections
Experimental procedures on mice were performed in accordance
withNational InstitutesofHealth (NIH)AnimalResearchAdvisory
Committee (Bethesda,MD,USA) and based on the Association for
Assessment and Accreditation of Laboratory Animal Care In-
ternational (Frederick, MD, USA) guidelines. 129-Sirt1tm1Mcby mice
were purchased from RIKEN BioResource Center (Ibaraki, Japan),
carrying a Sirt1 heterozygote genotype (29). 129-Sirt1tm1Mcby mice
were outbred with CD1 mice, to increase the chances of null mice
survivingafterweaning.Heterozygoteswere then inbredforupto4
generations, to generate wild-type (WT) and Sirt1-knockout
(KO) mice. Mice were raised in 12 h light/dark cycles and
received food and water ad libitum. Male and female mice
were euthanized at 1 or 12 wk for analysis of articular joints.
Humanchondrocyteswere isolated frompatientsundergoing
total knee arthroplasty.Non-OAknee sampleswere providedby
National Disease Research Interchange (Philadelphia, PA,USA).
The average age was 62 yr (range, 52–71). Chondrocyte isola-
tion and culture were performed as described elsewhere (30).
Monolayer cultures were maintained in DMEM supplemented
with 10% fetal bovine serum (FBS), 50 U/ml penicillin, and
50 mg/ml streptomycin (Biologic Industries, Beit-Haemek
Kibutz, Israel). The cells were treated with the proinflammatory
cytokines IL1b (5 ng/ml) and TNF-a (50 ng/ml; both from
Peprotec, Rehovot, Israel) in defined serum-free medium (BIO-
MPM 1; Biologic Industries, Beit-Haemek Kibutz, Israel). Con-
ditionedmediumwas filteredwith a 10-kDa cutoff Amicon filter
(EMD-Millipore, Billerica, MA, USA) and processed for immu-
noblot analysis.
Retroviral infections for Sirt1 and pHan (control) were per-
formed (31).All transient transfectionexperimentswere initiatedon
50%confluentmonolayercultures.Plasmids (4mg)were transfected
by Amaxa nucleofection for human chondrocytes (Amaxa, Basel,
Switzerland), according to themanufacturer’s protocol. Thehuman
pcDNA_SIRT1 expression plasmid was a kind gift of Prof. Danny
Reinberg(NewYorkUniversitySchoolofMedicine,NewYork,NY,
USA) The LEF1 expression plasmid (Pbabe-puroLEF1) was pur-
chased from Addgene (27023; Cambridge, MA, USA). Small in-
terferingRNAs (siRNAs) for SIRT1 andLEF1werepurchased from
Ambion (Thermo Fisher Scientific, Waltham, MA, USA) and used
according to the manufacturer’s recommendations. Sirt1 activity
wasmodulatedby the inhibitornicotinamide (NAM,10mM)or the
activator Res (1 mM; Sigma-Aldrich, St Louis, MO, USA).
Direct chondrogenesis differentiation protocol
MAN7 human embryonic stem cells (hESCs) were cultured as
previously described byOldershaw et al. (32) and Cheng et al. (33)
with slight modifications. hESCs were cultured in a feeder-free
system on vitronectin-coated (Thermo Fisher Scientific) tissue
culture plates with mTESR1 medium (StemCell Technology,
Vancouver, BC, Canada) and subcultured using EDTA passage.
For differentiation toward chondroprogenitors, a defined 3-stage
protocol was used (32). In brief, hESCs were transferred to fibro-
nectin (EMD-Millipore)-coated tissue culture wells (d 0) and ini-
tially differentiated toward primitive streak mesentoderm by
addition ofWnt3a, activinA, and fibroblast growth factor (FGF)-2
(d 1–3), followed by FGF2, bone morphogenic protein (BMP)-2
(substitution for BMP4; unpublished data), and follistatin, to pro-
mote mesoderm-like cells (d 4–7). Finally, cells were cultured in
FGF2, growth differentiation factor (GDF)-5, and BMP2 to pro-
mote chondrogenesis (d 8–10) and levels of FGF2 and GDF5 (d
11–13). Samples were collected every day for gene expression
analysis.
RNA isolation and PCR analysis
Total RNAwas extracted from cells using the RNeasy kit (Qiagen,
Valencia, CA, USA) after the manufacturer’s recommendations.
Oligo dT was used as the primer in the reverse-transcription re-
action. Real-time quantitative PCR (qPCR) reactions were per-
formed with 10 ng of cDNA and Syber Green mix (BioRad
Laboratories, Hercules, CA,USA) (31). Quantitative analyseswere
performedwith iCyclersoftware (Bio-Rad,Hercules,CA,USA).All
RNAsampleswere treatedwithDNase I before the PCR reactions.
Primers used: GAPDH-forward (F): 59–TACTAGCGGTTT-
TACGGGCG–39, reverse (R): 59–TCGAACAGGAGCAGAGA-
GCGA–39; SIRT1-F: 59–CAGATTAGTAGGCGGCTTGA–39, R:
59–CTAAACTTGGACTCTGGCAT–39; MMP-1- F: 59–AGTGA-
CTGGGAAACCAGATGCTGAM–39, R: 59–TCAGTGAGGAC-
AAACTGAGCCACA–39; MMP3-F: 59–TCCCTCAGGAAGCT-
TGAACCTGAA–39, R: 59–AAACCTAGGGTGTGGATGCCT-
CTT–39; MMP-8-F: 59–AATCCTTGCTCATGCCTTTCAGCC–39,
R: 59–GTGTTGGTCCATGTTTCTTCGGCA–39; MMP-13-F:
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59–AGTTTGCAGAGCGCTACCTGAGAT–39, R: 59–TTTGC-
CAGTCACCTCTAAGCCGAA–39; ADAMTS4-F: 59–ACAA-
AGATCCAGGAAAGGAGGGCT–39, R: 59–AGGGCTGAGG-
ACCGTTAAAGGAAA–39; ADAMTS-5-F: 59–TTCAACGTC-
AAGCCATGGCAACTG–39, R: 59–TGACGATAGGCAAAC-
TGCACTCCT–39; LEF1-F: 59–AATAAAGTCCCGTGGTGC–39,
R: 59–ATGGGTAGGGTTGCCTGAATC–39. Primers for de-
termining chondrogenesis were: COL2A1-F: 59–GGCAAT-
AGCAGGTTCACGTACA–39, R: 59–CGATAACAGTCTTGCC-
CCACTT–39; ACAN-F: 59–CATTCACCAGTGAGGACCTCG,
R: 59–TCACACTGCTCATAGCCTGCTTC–39; SOX9-F: 59–GA-
CTTCCGCCACGTGGAC–39, R: 59–GTTGGGCGGCAGGTA-
CTG–39. Values were normalized to GAPDH, which was
unaffected by the experimental treatments.
Chromatin immunoprecipitation
To perform chromatin immunoprecipitation (ChIP) assays, we
treatedhumanchondrocytes (P0–P2)with5ng/ml IL1b for 24h,
washed them with PBS, and cross-linked them with 1% form-
aldehyde for 10min at room temperature. Cells were then lysed
[lysis buffer; 10 mM EDTA, 50 mM Tris-HCl (pH 8.0), 1% SDS]
and sonicated (Vibra Cell; Sonics and Materials, Newtown, CT,
USA) at 50 cycles of 95% amplitude for 30 s, followed by a 45 s
incubation on ice, based on Bar Oz et al. (34). Samples were then
processed using the Low Cell ChIP kit (Diagenode, Lie`ge, Bel-
gium). After DNA isolation, qPCR reactions were performed
with primers flanking the conserved Lef1 binding within the 39
region of genomic human MMP13 (NG_021404) based on pre-
vious reports (25). Essentially, the corresponding human motif
within the 39 gene loci of MMP13 (16,566-16,625 bp) carrying
the conserved LEF1 binding site (CTTTGA) was chosen for
amplification (F: 59–AGCATCTGGAGTAACCGTATTG–39; R:
59–CCAGCCACGCATAGTCATATAG–39). Human IGX1A
Negative Control (Qiagen, Hilden, Germany) containing an
open-reading-frame–free intergenic region, was used as a neg-
ative control for all ChIP samples.
Protein and immunoblot analyses
Cell lysis and the generation of protein extracts were performed
as has been described (31). The protein extracts were then electro-
phoretically resolved by SDS-PAGE (10–20 mg protein/lane) and
transferred onto PVDF membranes for immunoblot analysis. The
blots were processed (19–21) and then probed with the indicated
antibodies. The after antibodies were used for b-actin (47778; Santa
Cruz Biotechnology, TX, USA), a2tubulin (T5168; Sigma-Aldrich),
SIRT1(07-131;EMD-Millipore),Ac-H3K9/14(A-4021-050; EMD-
Millipore), 2MeH3K9 (07441; EMD-Millipore), MMP13 (sc-
81547; Santa Cruz Biotechnology), LEF1 (2230; Cell Signaling
Technology ), and b-catenin (ab16051; Abcam, Cambridge,
United Kingdom). Immunoblots were developed using sec-
ondary antibodies to either alkaline phosphatase (BCIP/NBT
as a color developer) or horse radish peroxidase (chemi-
luminescence) and exposed to preflashed X-ray film. All im-
munoblotswere scanned in high resolution, and band intensity
was determined with ImageJ software (NIH, Bethesda, MD,
USA). Semiquantitative band intensities were normalized to
the corresponding housekeeping protein appearing on the blot.
MMP and SIRT1 enzyme activity
MMPActivity Assay Kit (ab112146; Abcam) uses a fluorescence
resonance energy transfer quenched peptide, as a generic MMP
activity indicator. Upon MMP cleavage, the fluorescence is re-
covered and read by a fluorescence microplate reader at 490 nM
(excitation) and 525 nm (emission) per microgram protein.
SIRT1 enzymatic activity was assessed by use of A Fluor de
Lys fluorescence assay kit (Enzo Life Sciences, Farmingdale, NY,
USA) (31). Values are presented as substrate conversion per
microgram protein.
Reporter assay
The TOPFlash or FOPFlash luciferase reporter plasmid
(EMD-Millipore) was cotransfected in human chondrocytes
with a control vector (pcDNA3) or the SIRT1/LEF1 expression
vectors, via Amaxa Nucleofector Technology Amaxa Bio-
systems, Cologne, Germany) in accordance with the manu-
facturer’s instructions. Two days after transfection, cells were
lysed using the passive lysis buffer (Promega, Madison, WI,
USA) and luciferase activity in the extractswasmeasuredusing
the dual luciferase assay system (Promega). Cotransfection
with the Renilla vector allowed normalization of the assays for
differences in transfection efficiency.
Immunohistochemistry
Human and murine samples were subjected to 2 d of tissue fix-
ation in 4% formalin and 14 d of decalcificationwith 10% EDTA.
Samples were dehydrated with a graded series of ethanol
washes, embedded in paraffin, and sectioned into 5-mm slices.
Sectionsweredigestedwith1mg/mlhyaluronidase inPBSatpH
6 (H3506; Sigma-Aldrich) for 1 h at 37°C and stainedwith aDAB
substrate kit (DAB057) after overnight incubation with MMP13
andLEF1 primary antibody. ZytoChemPlus (Zytomed Systems,
Berlin, Germany) horseradish peroxidase polymer conjugated
anti-rabbit (ZUC032) was used as a secondary antibody. Nega-
tive controls were incubatedwith secondary antibody alone and
counterstained with hematoxylin.
To determineOAhistopathology inmurine samples, sections
were stained with 0.5% Safranin O and 0.1% Fast green after
using Weigert’s iron hematoxylin (1.15973; Merck, Darmstadt,
Germany). OAhistopathologywas carried out based onGlasson
et al. (35).
Statistical analysis
Statistical significancewas assumed for confidence levels greater
than 95% (P, 0.05). Mann-Whitney analysis was performed to
determine the differences between 2 equivalent treatments
within a group (n. 4). Error bars indicate the standarddeviation
around the mean value, unless otherwise indicated.
For immunohistochemistry the percentage of cells per field
stained positive was determined. Stained cells are reflective of
greater than 10-fold intensity above the background (as de-
termined by scanning densitometry). An average of 10 fields
from 3 sections of 6 separate murine WT and Sirt12/2 mice, as
well as OA and non-OA cartilage samples were assessed (n = 6).
Each field was blindly read by 2 different individuals.
RESULTS
Overexpression of SIRT1 in human
chondrocytes leads to repression of MMP3, -8,
and -13 and ADAMTS4 gene expression
Inspectionof primaryhumanchondrocytes obtained from
OA and non-OA donors showed increasedMMP13 tissue
staining and mRNA expression in OA-derived tissue
(Fig. 1A), which also corresponded with a reduction in
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SIRT1 activity in OA. To determine whether SIRT1may
negatively regulate MMP13 expression, murine Sirt1
was then stably overexpressed in human OA chon-
drocytes by retroviral expression vector. In line with
previous reports (31), stable overexpression of murine
Sirt1 in human chondrocytes was confirmed via im-
munoblot analysis and associated with decreases in
H3K9/14 acetylation, as compared to unchanged
methylation of dimethyl-H3K9 and increased Sirt1 ac-
tivity (Fig. 1B). Next, we analyzed mRNA from chon-
drocyte lines for catabolic gene expression (Fig. 1C).
Cells overexpressing Sirt1 displayed significant de-
creases in MMP13 gene expression (5-fold), along with
MMP3 and -8, whereas MMP1 gene expression
remained unaffected compared to vector control, Sirt1
also repressed ADAMTS4, whereas ADAMTS5 was
unaffected. Ectopic overexpression of SIRT1 (;90%
transfection efficiency; Fig. 2A), resulted in a reduction
in cellular and secreted MMP13 protein, which was
additionally reflected by mRNA levels and MMP13
enzymatic activity (Fig. 2C). Treating passage 0 chon-
drocytes with Res (1 mM), an activator of Sirt1, reduced
cellular MMP13 protein level, mRNA expression and
activity, as compared to untreated controls (Fig. 2B,D).
Res treatment generated a 60% increase in Sirt1 activity
(Fig. 2B). Overall, these data imply that SIRT1 may re-
press MMP13 gene expression, as well as other proca-
tabolic genes in chondrocyte lines.
Down-regulating SIRT1 in human
chondrocytes leads to induction of MMP13
To investigate this observation further, we performed the
reverse experiment, in which SIRT1 siRNA was trans-
fected into chondrocytes to reduce SIRT1 protein levels.
SIRT1 protein and mRNA levels dropped signifi-
cantly after SIRT1 siRNA transfection (Fig. 3A). As a
result, MMP13 gene expression and activity increased
Figure 1. Stable Sirt1 expression in human OA chondrocytes leads to repression of MMP and ADAMTS family members. A)
Representative immunostained sections derived from patients with OA and non-OA donors (n = 4), quantiﬁed for the amount of
MMP13-stained cells within a ﬁeld. Right: qPCR for MMP13 mRNA from primary chondrocytes (OA vs. non-OA), which were
normalized to GAPDH values. The rightmost panel shows SIRT1 activity for non-OA and OA primary chondrocytes (n = 5). B)
Immunoblots from human OA chondrocyte extracts from cells stably overexpressing Sirt1 (or the retroviral control pHan) with
the indicated antibodies (n = 4). Bottom: cell extracts tested for Sirt1 enzymatic activity. C) mRNA from cells as in B was used in
qPCR reactions with the indicated human primers. Error bars indicate SD. *P , 0.05.
SIRT1 REPRESSES MMP13 GENE EXPRESSION 3119
Downloaded from www.fasebj.org by (86.141.248.194) on February 12, 2018. The FASEB Journal Vol. 31, No. 7, pp. 3116-3125.
significantly. We next treated passage 0 chondrocytes
with (10mM),which is a direct inhibitor of SIRT1 (36, 37).
After NAM treatment of chondrocytes, we observed a
70% reduction in SIRT1 enzymatic activity and a corre-
sponding 75% increase in acetylation of histone H3K9/
K14 (data not shown). Figure 3B shows clear increases in
MMP13 mRNA, cellular protein levels, and enzymatic
activity in the NAM-treated cells. This NAM-mediated
increase in MMP13 mRNA occurred even in cells that
overexpressed SIRT1, indicating that NAM can over-
come the repressive effects of SIRT1 on MMP13 gene
expression.
Induction of MMP13 by IL-1b is partially
repressed by SIRT1 overexpression
Asmentioned, data fromother studies have established that
LEF1 is necessary forMMP13gene expressionduring IL-1b-
challenge (21–26). Thus far, we have demonstrated that
SIRT1 repressed MMP13 gene expression; however, the
mechanismbywhich this is achieved is still unclear.Wenext
attempted to decipher whether SIRT1 reverses the effect of
Figure 2. Ectopic expression of SIRT1 in human OA
chondrocytes leads to reduced MMP13 gene expression and
activity. A) Human OA chondrocytes were transfected with a
SIRT1 expression plasmid or pcDNA plasmid control (empty
vector) (n = 4). Extracts generated at 48 h post-transfection
were used in immunoblot analysis or SIRT1 activity assay. B)
Chondrocytes treated with or without Res (1 mM) were used in
immunoblot analysis or SIRT1 activity assay (lower panel) (n =
4). C) Cells treated as in A were immunoblotted for cellular
MMP13 or secreted (s)MMP13, which was collected and
concentrated from conditioned medium. D) Cells treated as
in B were subjected to qPCR analysis for MMP13, and
MMP activity of cellular extracts was determined. qPCR values
were normalized to GAPDH values. Error bars indicate SD.
*P , 0.05.
Figure 3. Down-regulation of SIRT1leads to augmented
MMP13 levels. A) P1 chondrocytes transfected with a control
or SIRT1 siRNA and analyzed for SIRT1 activity, qPCR for
MMP13 and SIRT1, and MMP activity (n = 4). B) P0
chondrocytes treated, with or without NAM (10 mM), for
24 h and analyzed for SIRT1 activity, qPCR for MMP13 and
SIRT1, and MMP activity (n = 4). qPCR values were normalized
to GAPDH values. Error bars indicate SD. *P , 0.05.
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LEF1-mediatedMMP13geneexpression inan inflammatory
milieu exerted by IL1b (21–26). IL-1b up-regulates MMP13
gene expression 5-fold, consistent with previous reports (8)
(Fig. 4A). Overexpressing SIRT1 with IL-1b induction sig-
nificantly reduced MMP13 at the level of mRNA, protein,
and enzymatic activity by ;5-fold as compared to IL-1b
stimulationwithpcDNAcontrol (Fig. 4). Thesedata indicate
that IL-1b induces MMP13 through a mechanism at least
partly influenced by the action of SIRT1, given that intact
SIRT1 significantly lowered the maximum amount of
MMP13 inducedby IL-1b stimulation. Inpreviouswork,we
found that stimulation of chondrocyteswith IL1b, TNFa, or
both elicits SIRT1 truncation (27, 38), leading to its reduced
chromatin binding of COL2A1 (28). The truncated SIRT1
variant may possess impaired chromatin binding and thus
render diverse expression of its gene targets.
The transcription factor LEF1 is a
transactivator of MMP13 and is
down-regulated by SIRT1
To identify the underlying mechanism by which SIRT1
inhibitsMMP13 gene expression, we focused on the LEF1
transcription factor, given that it is implicated in IL-1b-
mediated cartilage degeneration in arthritis (21–26). The
transcription factor LEF1 has been shown to positively
regulate MMP13 transcription in chondrocytes via an
enhancer sequence at the 39 region of the gene (25).
Overexpression of LEF1 in chondrocytes led to increases
in bothMMP13protein andmRNAlevels (Fig. 5A).When
LEF1 siRNA was transfected into human chondrocytes,
LEF1 and MMP13 protein (Fig. 5B) and mRNA levels
were significantly reduced. These data, supported by
previous findings, demonstrate a close correlation be-
tween LEF1 and MMP13 gene expression.
When LEF1 levels were assessed in SIRT1-expressing
cells, it was apparent that both LEF1 protein (Fig. 5C) and
mRNA levels (Fig. 5D) were reduced in the presence of
SIRT1. When endogenous SIRT1 levels were reduced by a
SIRT1 siRNA, both LEF1 protein and mRNA levels were
elevatedsignificantly (Fig. 5E), corresponding to increases in
MMP13 levels (as in Fig. 3A). To assess transcriptionactivity
of LEF1, we used the TOPFlash construct containing a
promoter consisting of LEF1 sites fused to a luciferase-
encoding gene. Cotransfection of SIRT1 with TOPFlash
significantly reduced luciferase levels, as compared to
pcDNA controls (Fig. 5F). Knocking down LEF1 with
TOPFlash in chondrocytes showed an ;2-fold decrease in
luciferase activity (Fig. 5G), supporting that SIRT1 over-
expression indeed reduced luciferase intensity of TOPFlash
via down-regulating LEF1 expression. As the control, we
cotransfected TOPFlash with LEF1-expressing vector and
observed a 2-fold increase in luminescence compared with
pcDNAcontrol (Fig.5H).Takentogether, thesedata indicate
that SIRT1 represses LEF1 gene expression, which is tightly
linked to MMP13 gene expression in human chondrocytes.
To further assess whether the SIRT1 repressive effects
on LEF1 are conserved throughout chondrogenesis, we
used a previously described 3-step protocol in which hu-
man embryonic stem cells are efficiently directed toward
chondrogenesis (32, 33). At d 13 of chondrogenesis, SOX9,
COL2A1, and ACAN gene expression was significantly
increased compared to d 0 (Fig. 5I). During d 10 and 13 of
chondrogenesis, SIRT1 gene expression levels were re-
duced 2-fold (Fig. 5J), whereas LEF1 gene expression was
augmented 15-fold, compared to d 4 and 8. These data
provide evidence that the repressive effect of SIRT1 on
LEF1 levels is developmentally conserved.
MMP13 and LEF1 gene expression in articular
cartilage of Sirt1 KO mice and human OA
To examine the role of SIRT1 in regulating MMP13 in vivo
we explored the expression of this protease in an animal
model, Sirt12/2mice (29). We assessed 1-wk-old Sirt12/2
andWTmice forMMP13 andLEF1 levels in the superficial
zone fromarticular cartilage of distal interphalangeal joints
in the anterior paws. As shown by immunohistochemistry
in Fig. 6A, the staining intensity for MMP13 and LEF1
appeared elevated in the articular cartilage of the Sirt12/2
Figure 4. Induction of MMP13 by IL-1b is partially repressed by SIRT1 overexpression. Human OA chondrocytes transfected with
a SIRT1 expression plasmid or plasmid control (pc)DNA (empty vector) were treated with or without IL-1b (10 ng/ml) for 24 h
(n = 6). mRNA and protein extracts were generated and processed for qPCR (A) and for immunoblots (B), and the medium was
assessed for MMP activity (C). qPCR values were normalized to GAPDH values. Error bars indicate SD. *P , 0.05.
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mice, compared with the WT mice, which is quantified in
graphs. Scoring 4–6-mo-old mice for OA severity in the
medial tibial plateau showed significant increases in OA
severity in Sirt12/2mice in the lateral compartment, and a
(30%) reduction in cartilage thickness in both medial and
lateral compartments of the tibial plateau in KO mice
compared with age-matched WT mice (Fig. 6B, C, re-
spectively). Of note, among the WT mice, both males and
females did not display significant differences in OA se-
verity, in tibial and femoral condyles.
Because the levels of SIRT1 are reduced in human OA
cartilage andchondrocytes (28, 38), LEF1 levels are expected
to be elevated in the affected tissue, with a corresponding
elevation in MMP13. As predicted and shown in Fig. 6D,
LEF1 levels were indeed elevated in the cartilage from
patients with OA.Moreover, this increase appears to be
significant, as shown in the right panels. Accordingly,
LEF1 protein levels were elevated in OA cartilage tis-
sues, whereas SIRT1 levels were reduced. Furthermore,
OA-derived chondrocytes treated with IL1b or IL1b/
TNFa showed increased MMP13 expression (Fig. 6E),
which was accompanied by truncated SIRT1 and in-
creased LEF1 protein levels, as compared to untreated
cells (Fig. 6F). ChIP analysis for the human MMP13 39
region bearing the conserved LEF1 binding site did not
show enrichment for SIRT1; rather, LEF1 increased
significantly upon IL1b/TNFa challenge. These data
support that during OA, reduced SIRT1 activity corre-
lates with increased LEF1 levels, ultimately leading to
enhanced MMP13 gene expression in chondrocytes.
Figure 5. LEF1 mediates induction of MMP13 and is repressed by SIRT1. A) Immunoblots and qPCR of protein and mRNA from
human OA chondrocytes, transfected with a vector control- or LEF1-expressing construct. B) Immunoblots and qPCR of protein
and mRNA from human OA chondrocytes transfected with a control siRNA or LEF1 siRNA. C) Immunoblots and band intensity
of human OA chondrocytes transfected with a vector control- or SIRT1-expressing construct, treated with or without IL-1b
(n = 6). D) Human OA chondrocytes transfected with SIRT1 or pcDNA and analyzed via qPCR for LEF1 gene expression. E)
Human OA chondrocytes transfected with a control siRNA or SIRT1 siRNA were analyzed via immunoblot analysis and qPCR. F)
Luciferase activity in human OA chondrocytes transfected with a vector control- or SIRT1-expressing construct along with either
a LEF1 target promoter/luciferase construct (TOPFlash) or a control promoter/luciferase construct (FOPFlash) (n = 6). G, H)
Luciferase activity in human OA chondrocytes transfected with LEF1 siRNA (G) or LEF1-expressing construct (H) along with
TOPFlash promoter/luciferase construct (n = 6). I) SOX9, COL2A1, and ACAN gene expression in d 0 (black bars) and d 13
(gray bars) of chondrogenesis protocol (n = 4). J ) SIRT1 and LEF1 mRNA expression at d 0, 4, 8, 10, and 13 of hESC
chondrogenesis (n = 4). Error bars indicate SD. *P , 0.05, **P , 0.01, ***P , 0.001.
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DISCUSSION
In this study,we attempted to decipher themechanism by
which SIRT1 regulatesMMP13 gene expression in human
OA chondrocytes. Our results support previous observa-
tions regarding thepivotal roleLEF1plays inMMP13gene
expression (21–26) and add a new facet to our knowledge
on LEF1 regulation, which until now had been unknown.
Figure 6. MMP13 and LEF1 are elevated in the articular cartilage chondrocytes of Sirt12/2 mice as well as human OA cartilage.
A) Superﬁcial zones from articular cartilage of interphalangeal joints (anterior paws) from WT mice (+/+) and Sirt12/2 mice
were examined for MMP13 and LEF1 levels by immunohistochemistry. Magniﬁcation, 320. Control sections with only the
secondary antibody show the level of background staining (n = 6). B) OA scoring based on Glasson (35) for WT (3 males and
4 females; n = 7) and Sirt12/2 mice (2 males, 4 females; n = 6), age 4–6 mo. Magniﬁcation, 320. C) Representative safranin
O/ Fast green staining for medial and lateral joint compartments. D) Non-OA and OA human cartilage samples were subjected
to immunohistochemistry for LEF1. Magniﬁcation, 320. Control sections with only the secondary antibody show the level of
background staining. A) The average number of positive stained cells per ﬁeld. An average of 10 ﬁelds from 3 sections of
6 separate Sirt1 WT mice, Sirt12/2 mice, human OA, and human non-OA cartilage samples were assessed (n = 6). E) Human
chondrocytes treated with IL1b (5 ng/ml) and TNF-a (50 ng/ml) and analyzed for MMP13 expression (n = 6); SIRT1 and LEF1
protein levels, n = 5, with band quantiﬁcation for LEF1 protein bands. G) ChIP analysis for chondrocytes treated as in E, targeted
the conserved Lef1 binding within the 39 region of genomic human MMP13 (NG_021404, 25) to monitor SIRT1 and LEF1
enrichment (n = 4). Error bars indicate SEM. *P , 0.05 based on Mann-Whitney analysis.
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We report for the first time, to our knowledge, that SIRT1
is a negative regulator of LEF1 gene expression and thus
indirectly represses MMP13 gene expression. During OA,
proinflammatory conditions elicit loss of SIRT1 enzymatic
activity via SIRT1 cleavage (27), potentially lifting its re-
pressive effect on LEF1 and causing enhanced LEF1 gene
expression, as we show in this report.
On a developmental level, Wnt signaling is critical for
endochondral ossification and skeletal development. The
canonical Wnt pathway consists of Wnt ligands interact-
ing with the FRIZZLE receptor, inhibiting glycogen syn-
thase kinase (GSK)-3b, and phosphorylation ofb-catenin,
resulting in b-catenin stabilization, which then enables its
transcriptional transactivation together with T-cell factor
(TCF)/LEF complex in the nucleus. In adulthood and
aging, b-catenin activation is associated with enhanced
cartilage ossification and degeneration via augmented
MMP levels (39–42). Furthermore, procatabolic cytokines,
such as IL-1b, induce Wnt protein expression, which
elicits b-catenin activation (39). In fact, the Wnt protein
familymemberWnt7b isup-regulated inbothRAandOA
synovium (42), which supports its contribution to carti-
lage destruction. Moreover, it has been shown that in-
hibition of GSK3b results in stable cellular b-catenin and
induces OA-like features in vivo (41). On the other hand,
Ma and colleagues (39) established that Wnt/b-catenin
(i.e., Wnt3a), in a LEF1-independent manner, possessed an
anticatabolic role and inhibited the expression ofMMP-
1,-3, and -13 under IL-1b stimulation in primary human,
murine, and bovine articular chondrocytes. Therefore,
there are several canonical and noncanonical effects of
Wnt signaling that modulate OA pathogenesis.
Another mode of regulating b-catenin stability was re-
ported by Simic et al. (43) who showed that SIRT1 deacety-
lates b-catenin and thus renders it stable and capable of
transactivating its nuclear targets toward osteogenic differ-
entiation.ThisSIRT1-relatedpathway is less likely tooccur in
OA, because SIRT1 possesses reduced activity in OA carti-
lage, which is expected to lead to maintenance of b-catenin
acetylation levels and its exclusion fromthenucleus. SIRT1
may affect not only b-catenin but also its downstream
transactivating partners, as we showed in this study.
A growing body of evidence points to SIRT1 as a potent
repressor ofMMP13 gene expression in cultures of primary
humanOA chondrocytes (27, 44, 45). The results presented
here show that SIRT1 represses LEF1 gene expression,
which activates MMP13 gene expression. Studies have
shown that SIRT1 can demonstrate a broad anti-
inflammatory function in a variety of tissues (44–49). For
example, in chronic obstructive pulmonarydisorder, SIRT1
exerts a protective effect, partially because of its capacity to
down-regulate MMP9 (49), and modulating NFkB activity
during thedisease (48). In addition to theknown functionof
SIRT1 in repressingMMP9 inmacrophages andmonocytes
(49),wedemonstrated thatSIRT1repressesMMP13, aswell
as MMP3 and -8, in chondrocytes. Thus, suggesting that
part of the SIRT1 anti-inflammatory function is to repress
the expression of these matrix-degrading enzymes, as was
demonstrated here both in vitro and in vivo.
Although the exact mechanism, by which SIRT1 targets
theLEF1gene is not completely known, ourdata show that
SIRT1hasa strong repressiveeffect onLEF1expression,not
only in articular cartilage, but also during chondrogenesis,
indicating that this is a highly conserved mechanism. In
conclusion, our data provide further support that activa-
tion of SIRT1 plays a positive role in blocking or reducing
the severity of OA, in part through its ability to repress the
expression of MMPs. Future efforts should be aimed at
deciphering newmechanisms involved in this process.
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